Potentiation of arsenic trioxide-induced apoptosis by retinoic acid in retinoic acid sensitive and resistant HL-60 myeloid leukemia cells

Chinese Medical Journal

Volumn 113, Issue 6, 2000, Pages 498-501

  Huang, Xiaojun J ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Arsenic trioxide (As2O3); HL 60 cells; Retinoic acid (RA)

Indexed keywords

ALITRETINOIN; ARSENIC TRIOXIDE; RETINOIC ACID; RETINOIC ACID RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL GROWTH; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; GENE INACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; LEUKEMIA CELL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; CELL DIVISION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HL-60 CELLS; HUMANS; OXIDES; TRETINOIN;

EID: 0033917585     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Zhang P, Wang SY, Hu XH. Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin J Hematol 1996;17:58-60.
2. 3) in the treatment of acute promyelocytic leukemia (APL) : II . clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 9:3354-3360.
3. 3 induces NB4 cell apoptosis with downregulation of bcl-2 expression and alteration of PML-RAR/PML protein localization. Blood 1996;88:1052-1061.
4. Zhu J, Koken MHM, Quignon F, et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci U S A 1997; 94: 3978-3983.
5. Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72: 567-572.
6. Degos L, Dombret H, Chomienne C, et al. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995;85:2643-2653.
7. 3 exerts dose-dependent dual effects on APL cells. Blood 1997; 89:3345-3353.
8. 3 induced apoptosis and loss of PML/RARα protein in both retinoid sensitive and resistant APL cells. J Natl Cancer Inst 1998;90:124-133.
9. Chang KS, Fan YH, Andreeff M, et al. The PML gene encodes a phosphoprotein associated with the nuclear matrix. Blood 1995;85:3646-3653.
10. Daniel M, Koken M, Romagne O, et al. PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood 1993;82:1858-1867.
11. Mu ZM, Chin KV, Liu JH, et al. PML, a growth suppressor disrupted in acute promyelocyte leukemia. Mol Cell Biol 1994; 14: 6858-6867.
12. Ahn MJ, Nason-Burchenal K, Moasser M, et al. Growth suppression of acute promyelocytic leukemia cells having increased expression of the non-rearranged alleles: RARα or PML. Oncogene 1995;10:2307-2314.
13. Konig A, Wrazel L, Warrell Jr RP, et al. Comparative activity of Melarsaprol and arsenic trioxide on chronic B-cell leukemia lines. Blood 1997;90:562-570.
14. Gallagher RE, Bilello PA, Ferrari AC, et al. Characterization of differentiation-inducer-resistant HL-60 cells. Leuk Res 1985;9:967-986.
15. Gorczyca W, Bigman K, Mittelman A, et al. Induction of DNA strand breaks associated with apoptosis during treatment of leukemias. Leukemia 1993;7:659-670.
16. Gong J, Li X, Darzynkiewicz Z. Different patterns of apoptosis of HL-60 cells induced by cycloheximide and camptothecin. J Cell Physiol 1993;157:263-270.
17. Li YP, Said F, Gallagher R. Retinoic acid-resistant HL-60 cells exclusively contain mutant retinoic acid receptor-alpha. Blood 1994;83:3298-3302.